Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Medivation Gets $110M Upfront From Astellas In Prostate Cancer Collaboration

This article was originally published in PharmAsia News

Executive Summary

Medivation has been here before and apparently likes the terrain. In a deal similar to last year's partnership with Pfizer on Dimebon, the company announced on Oct. 27 that it will receive a $110 million upfront payment to collaborate with Astellas on the development and commercialization of its Phase III prostate cancer candidate MDV3100

You may also be interested in...



Japan Earnings Roundup: Astellas' Oncology Gains, Eisai Hit Hard, KHK Domestic Strength

Astellas Pays $125 Million Up-Front To Share Rights To AVEO's Tivozanib

Astellas Pharma Inc. has fortified its oncology business by striking a deal to share development and commercialization of AVEO Pharmaceuticals Inc.'s Phase III cancer drug tivozanib in territories beyond Asia

Astellas Pays $125 Million Up-Front To Share Rights To AVEO's Tivozanib

Astellas Pharma Inc. has fortified its oncology business by striking a deal to share development and commercialization of AVEO Pharmaceuticals Inc.'s Phase III cancer drug tivozanib in territories beyond Asia

Table

View full table

Related Content

Pink Sheet
Scrip
Pink Sheet
Scrip
Scrip
Tags:
Latest Headlines

Metsera Launches As New Obesity Contender Flush With $290m

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

See All
UsernamePublicRestriction

Register

SC070207

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By